CDK4/6 Inhibition Customizes Frontline HR+, HER2- mBC Treatment
According to Kimberly Podsada, BSN, RN, MSN, NP-C, CNS, the availability of 3 CDK4/6 inhibitors in first-line mBC therapy gives patients more choices.
Related Articles
FDA Approves Tafasitamab Combo for R/R Follicular Lymphoma
The FDA has approved tafasitamab in combination with lenalidomide and rituximab for adults with relapsed/refractory follicular lymphoma.
No One Should Face Cancer Alone: The Power of Community in Cancer Care
Ask patients, “Who’s in your corner?”
Nurses’ Role in Grief Support for Pediatric Brain Cancer Survival
Oncology nurses can help patients and families understand the expectations of pediatric brain cancer survival, says Kasey Rangan, MSN, CPNP-PC, CPHON.
Oncology Nurses Aid BC Survivorship and Lymphedema Prevention
Because oncology nurses are at the forefront of patient care, they are uniquely positioned to facilitate cancer survivorship and lymphedema prevention.
Opinion: Topical BRAF Inhibitor Could Reduce Rash in Anti-EGFR Therapy
Oncology nurses can play a key role in educating patients and supporting clinical trial participation for this new treatment option.
June 2025
Oncology Nursing News connects oncology nurses and APPs with updates on therapy advances, side effect management, and patient-centered cancer care.
Relacorilant/Nab-Paclitaxel Is Convenient, Safe in Ovarian Cancer
In addition to a significant PFS benefit vs nab-paclitaxel alone, the combination provides an at-home option for patients with ovarian cancer.
Neoadjuvant Nivolumab Regimen Improves OS in Resectable NSCLC
Nivolumab plus chemotherapy significantly improved OS vs chemo alone in resectable NSCLC, per updated CheckMate-816 findings.
Case Study: Bridging the Gap for Patients With Metastatic CRC
Advanced practice providers have the opportunity to instill hope in patients through education and personalized care.
FDA Approves Perioperative Pembrolizumab in Head and Neck SCC
The FDA approved a perioperative pembrolizumab regimen in head and neck squamous cell carcinoma, marking the first approval in this cancer type in 6 years.